Press Release: Novartis: New Kisqali(R) data -3-

13. Prat, A. et al. Response and survival of breast cancer intrinsic subtypes

following multi-agent neoadjuvant chemotherapy. BMC Med. 13, 1--11

(2015).

14. Llombart-Cussac, A. et al. HER2-enriched subtype as a predictor of

pathological complete response following trastuzumab and lapatinib

without chemotherapy in early-stage HER2-positive breast cancer (PAMELA):

an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol.

(2017) doi:10.1016/S1470-2045(17)30021-9.

15. Prat, A. et al. Prognostic Value of Intrinsic Subtypes in Hormone

Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or

Without Lapatinib. JAMA Oncol. (2016) doi:10.1001/jamaoncol.2016.0922.

16. Cardoso F et al. Assessment of quality of life (QOL) in patients with

advanced breast cancer (ABC) in clinical practice: a real-world

multi-country survey. Presented at the San Antonio Breast Cancer

Symposium, December 7-10, 2021. Abstract #P4-12-03.

17. Prat A et al. Genomic profiling of PAM50-based intrinsic subtypes in

HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies.

Presented at the San Antonio Breast Cancer Symposium, December 7-10,

2021. Abstract # PD2-05.

18. De Laurentiis M et al. Analysis of first-line (1L) patients (pts) with de

novo disease vs late relapse and all pts with vs without prior

chemotherapy (CT) in the MONALEESA-3 (ML-3) trial. Presented at the San

Antonio Breast Cancer Symposium, December 7-10, 2021. Abstract #

P1-18-11.

19. Bianchini G et al. Circulating tumor DNA (ctDNA) dynamics in patients

with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced

breast cancer (aBC) treated in first line with ribociclib (R) and

letrozole (L) in the BioItaLEE trial. Presented at the San Antonio Breast

Cancer Symposium, December 7-10, 2021. Abstract #GS3-07.

20. Kisqali (ribociclib) Prescribing information. East Hanover, New Jersey,

USA: Novartis Pharmaceuticals Corporation; July 2020.

21. Novartis Data on File. Novartis Pharmaceuticals Corp: 2021.

22. Novartis Pharmaceuticals and Translational Research in Oncology (2018,

December 7 - 2026, May 29). A Trial to Evaluate Efficacy and Safety of

Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With

HR+/HER2- Early Breast Cancer (NATALEE). Identifier NCT03701334.

https://clinicaltrials.gov/ct2/show/NCT03701334.

*Ibrance(R) is a registered trademark of Pfizer Inc.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Ashley Buford

Novartis External Communications Novartis Oncology Communications

+41 79 392 8697 (mobile) +1 201 953 4364

anja.von_treskow@novartis.com ashley.buford@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

Julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Thomas Hungerbuehler +41 61 324 8425 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

December 08, 2021 09:30 ET (14:30 GMT)